Alcon
Builds surgical eye-care systems, contact lenses, and ocular-health products for global markets.
Something off on this page? Send us feedback.
Profile
Develops surgical eye-care systems, implantables, and recurring procedure supplies while selling contact lenses and ocular-health products through Vision Care. The global model links equipment placements to consumable demand and depends on regulatory clearance, procedure volumes, supply continuity, clinical adoption, and professional and retail channels.
Develops eye-care products across two businesses: Surgical and Vision Care. Surgical supplies equipment, intraocular lenses, glaucoma devices, and recurring consumables for cataract, vitreoretinal, refractive-laser, and glaucoma procedures.
Sells daily and reusable contact lenses alongside lens-care, dry-eye, allergy, vitamin, redness-relief, and selected ophthalmic pharmaceutical products. Operations span more than 140 countries, with a Swiss headquarters and major operating and innovation activities in Fort Worth.
Combines internal research with acquisitions and product extensions, while installed surgical systems support recurring demand for proprietary supplies. Results depend on regulatory clearances, clinical adoption, procedure volumes, manufacturing quality, supply continuity, and professional, retail, distributor, and e-commerce channels.
Company facts
Categories
Key statistics
Year to date −7.2% · Average volume (30d) 1.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 13, 2026 | Exane BNP Paribas | Downgrade | Neutral | ||
| Aug 13, 2026 | BNP Paribas | Target | $79 | ||
| Aug 12, 2026 | UBS | Target | $91 | $35 | |
| Aug 12, 2026 | Mizuho Securities | Target | $80 | $85 | |
| Aug 11, 2026 | BTIG | Reiterate | Buy | $100 | $82 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | $0.77 | $0.84 | +9.1% | $2.72B | $2.79B | +2.5% | +2.34% |
| May 5, 2026Q1 FY26 | $0.80 | $0.85 | +6.2% | $2.64B | $2.65B | +0.4% | −12.14% |
| Feb 24, 2026Q4 FY25 | $0.79 | $0.78 | −1.3% | $2.69B | $2.64B | −1.9% | +2.54% |
| Nov 11, 2025Q3 FY25 | $0.77 | $0.79 | +2.6% | $2.71B | $2.61B | −3.6% | +2.69% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $2.47B | $2.60B | $2.61B | $2.72B | $2.65B | $2.76B | |
| Gross profit | $1.38B | $1.39B | $1.46B | $1.47B | $1.50B | $1.64B | |
| Operating income | $468.0M | $247.0M | $332.0M | $313.0M | $410.9M | $46.9M | |
| Net income | $350.0M | $176.0M | $237.0M | $217.0M | $185.3M | $0 | |
| Diluted EPS | $0.70 | $0.35 | $0.48 | $0.44 | $0.38 | $0.00 | |
| Gross margin | 55.9% | 53.5% | 55.8% | 54.2% | 56.4% | 59.3% | |
| Operating margin | 18.9% | 9.5% | 12.7% | 11.5% | 15.5% | 1.7% |
Fiscal years (4-quarter sums)FY21 $8.29B · FY22 $8.72B · FY23 $9.46B · FY24 $9.91B · FY25 $10.40B
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $1.46B · Total debt $5.30B · Total assets $31.10B · Shareholders' equity $21.60B
Dividends
Raised for 4 straight years — most recently to $0.3593 from $0.3334 in May 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| May 6, 2026 | May 6 | May 7 | $0.3593 | raised from $0.3334 |
| May 14, 2025 | May 14 | May 15 | $0.3334 | raised from $0.2647 |
| May 14, 2024 | May 15 | May 16 | $0.2647 | raised from $0.2357 |
| May 10, 2023 | May 11 | May 12 | $0.2357 | raised from $0.205 |
| May 3, 2022 | May 4 | May 5 | $0.205 |
Ownership
Shares outstanding 487.70M · Float 486.14M · 99.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 29.48M | 5.90% | 13G | Apr 23, 2025 |
| Vanguard Capital Management LLC | 14.75M | 3.02% | 13F | Aug 13, 2026 |
| Bank of New York Mellon Corp | 13.06M | 2.68% | 13F | Aug 6, 2026 |
| Norges Bank | 10.98M | 2.25% | 13F | Aug 12, 2026 |
| Invesco Ltd. | 10.38M | 2.13% | 13F | Aug 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Bausch + Lomb
Broad rival in lenses, ocular health, and ophthalmic surgery
- Johnson & Johnson
Competes across contact lenses and cataract implants
- CooperCompanies
Major contact-lens rival across daily and reusable modalities
- Glaukos
Focused rival in interventional glaucoma therapies
- STAAR Surgical
Focused refractive-surgery rival through implantable phakic lenses
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Alcon | $72.15 | +0.21% | $35.12B | 55.4 | 18.6 | 3.3 | +7.5% |
| Bausch + Lomb | $17.15 | 0.00% | $6.13B | — | 17.2 | 1.2 | +9.1% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| CooperCompanies | $71.17 | +0.01% | $13.88B | 60.3 | 15.0 | 3.3 | +7.9% |
| Glaukos | $179.87 | −0.01% | $10.61B | — | 1,404.1 | 17.3 | +49.5% |
| STAAR Surgical | $22.11 | +0.02% | $1.10B | 276.4 | 36.1 | 3.2 | +111.0% |
| Median | 60.3 | 22.4 | 3.3 | +9.1% |